Kairos Pharma, LTD.
KAPADrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
AR Blockade | Phase 2 | Castration-resistant Prostate Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Kairos Pharma, LTD.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Kairos Pharma, LTD.'s (KAPA) pipeline across Phase 2. Its lead program is AR Blockade (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Kairos Pharma, LTD.'s next FDA catalyst?→
Kairos Pharma, LTD.'s (KAPA) next tracked catalyst is a Earnings expected November 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track KAPA biotech catalysts?→
Add KAPA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Kairos Pharma, LTD.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.